Placebo-Controlled Trial of Cytisine for Smoking Cessation
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cytisine, a partial agonist that binds with high affinity to the α(4)β(2) nicotinic acetylcholine receptor, is a low-cost treatment that may be effective in aiding smoking cessation. This study assessed the efficacy and safety of cytisine as compared with placebo. METHODS: We conducted a single-center, randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive cytisine or matching placebo for 25 days; participants in both groups received a minimal amount of counseling during the study. The primary outcome measure was sustained, biochemically verified smoking abstinence for 12 months after the end of treatment. Of 1542 adult smokers screened, 740 were enrolled and 370 were randomly assigned to each study group. RESULTS: The rate of sustained 12-month abstinence was 8.4% (31 participants) in the cytisine group as compared with 2.4% (9 participants) in the placebo group (difference, 6.0 percentage points; 95% confidence interval [CI], 2.7 to 9.2; P=0.001). The 7-day point prevalence for abstinence at the 12-month follow-up was 13.2% in the cytisine group versus 7.3% in the placebo group (P=0.01). Gastrointestinal adverse events were reported more frequently in the cytisine group (difference, 5.7 percentage points; 95% CI, 1.2 to 10.2). CONCLUSIONS: In this single-center study, cytisine was more effective than placebo for smoking cessation. The lower price of cytisine as compared with that of other pharmacotherapies for smoking cessation may make it an affordable treatment to advance smoking cessation globally.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
Mortality in relation to smoking: 50 years' observations on male British doctors
Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004) · BMJ · doi:10.1136/bmj.38142.554479.ae · Cited by 2,920 · cited 1×
“Purportedly, every year that a smoker delays quitting beyond the mid-30s subtracts 3 months of life expectancy.(2) However, of the more than 1 billion smokers around the globe, two thirds reside in countries where the average household income is less than $200 per week and where therapy for this kind is not paid for b…”
BackgroundMoher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,832
Mackay, J. M., & Eriksen, M. P. (2002) · Medical Entomology and Zoology · Cited by 1,431
Shape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · cited 1×
“It is a highly addictive habit, with more than 95% of unaided attempts at cessation failing to last 6 months.(1) Purportedly, every year that a smoker delays quitting beyond the mid-30s subtracts 3 months of life expectancy.”
BackgroundAntidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Outcome criteria in smoking cessation trials: proposal for a common standard
West, R., Hajek, P., Stead, L., & Stapleton, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00995.x · Cited by 1,285
Self-citation
Research works printed but not linked: 5
- Cahill K, 2010, Cochrane Database Syst Rev, 12, CD006103
- Stead LF, 2008, Cochrane Database Syst Rev, 1, CD000146
- Hughes JR, 2007, Cochrane Database Syst Rev, 1, CD000031
- Tutka P, 2006, Pharmacol Rep, 58, 777
- Stoyanov S, 1965, Chimpharm Sofia, 2, 13
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 691
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Nicotinic acetylcholine receptors: From basic science to therapeutics
Hurst, R., Rollema, H., & Bertrand, D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.012 · Cited by 522
Bioactive Secondary Metabolites from Plant Sources: Types, Synthesis, and Their Therapeutic Uses
Twaij, B. M., & Hasan, M. N. (2022) · International Journal of Plant Biology · doi:10.3390/ijpb13010003 · Cited by 441
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Treatment of Tobacco Smoking: A Review
Rigotti, N. A., Kruse, G. R., Livingstone-Banks, J., & Hartmann-Boyce, J. (2022) · JAMA · doi:10.1001/jama.2022.0395 · Cited by 361
2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment
Barua, R. S., Rigotti, N. A., Benowitz, N. L., Cummings, K. M., Jazayeri, M.-A., Morris, P. B., Ratchford, E. V., Sarna, L., Stecker, E. C., & Wiggins, B. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.027 · Cited by 353
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Brewer, N. T., Hall, M. G., Noar, S. M., Parada, H., Stein-Seroussi, A., Bach, L. E., Hanley, S., & Ribisl, K. M. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2621 · Cited by 321
Le Foll, B., Piper, M. E., Fowler, C. D., Tonstad, S., Bierut, L., Lu, L., Jha, P., & Hall, W. D. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00346-w · Cited by 316
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 311
West, R., Raw, M., McNeill, A., Stead, L., Aveyard, P., Bitton, J., Stapleton, J., McRobbie, H., Pokhrel, S., Lester‐George, A., et al. (2015) · Addiction · doi:10.1111/add.12998 · Cited by 272
Self-citationCytisine versus Nicotine for Smoking Cessation
Walker, N., Howe, C., Glover, M., McRobbie, H., Barnes, J., Nosa, V., Parag, V., Bassett, B., & Bullen, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407764 · Cited by 239
Supporting smoking cessation: a guide for health professionals.
Zwar, N. A., RICHMOND, R. L., Borland, R., Peters, M. J., Litt, J., Bell, J., Caldwell, B., & Ferretter, I. T. (2012) · Cited by 226
Treating Smokers in the Health Care Setting
Fiore, M. C., & Baker, T. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1101512 · Cited by 198
Phytochemical and Pharmacological Importance of Plant Secondary Metabolites in Modern Medicine
Velu, G., Palanichamy, V., & Rajan, A. P. (2018) · Bioorganic Phase in Natural Food: An Overview · doi:10.1007/978-3-319-74210-6_8 · Cited by 159
Managing tobacco use: the neglected cardiovascular disease risk factor
Rigotti, N. A., & Clair, C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht352 · Cited by 182
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Grace, S. L., Turk-Adawi, K. I., Contractor, A., Atrey, A., Campbell, N. R. C., Derman, W., Ghisi, G. L. M., Sarkar, B. K., Yeo, T. J., Lopez-Jimenez, F., et al. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.004 · Cited by 166
Smoking cessation interventions for smokers with current or past depression
van der Meer, R. M., Willemsen, M. C., Smit, F., & Cuijpers, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006102.pub2 · Cited by 159
Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis
Hájek, P., McRobbie, H. J., & Myers, K. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-203035 · Cited by 161
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
“The α4β2 nAchR partial agonist cytisine has been used for decades as a smoking cessation drug in Eastern European countries and has been shown to be effective and safe as an aid for smoking cessation [122-125].”
BackgroundMinocycline: Therapeutic Potential in Psychiatry
Dean, O. M., Data-Franco, J., Giorlando, F., & Berk, M. (2012) · CNS Drugs · doi:10.2165/11632000-000000000-00000 · Cited by 131
“In this context, successful trials of smoking cessation have needed vastly greater statistical power to demonstrate effects.([84]) However, a trend towards amelioration of depressed mood and reductions in craving in abstainers was reported.”
BackgroundTutka, P., Vinnikov, D., Courtney, R. J., & Benowitz, N. L. (2019) · Addiction · doi:10.1111/add.14721 · Cited by 121
Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial
Courtney, R. J., McRobbie, H., Tutka, P., Weaver, N. A., Petrie, D., Mendelsohn, C. P., Shakeshaft, A., Talukder, S., Macdonald, C., Thomas, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.7621 · Cited by 118
Self-citationA survey of tobacco dependence treatment services in 36 countries
Raw, M., Regan, S., Rigotti, N. A., & McNeill, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02443.x · Cited by 118
A survey of tobacco dependence treatment services in 121 countries
Piné‐Abata, H., McNeill, A., Murray, R., Bitton, A., Rigotti, N., & Raw, M. (2013) · Addiction · doi:10.1111/add.12172 · Cited by 114
Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice
Giulietti, F., Filipponi, A., Rosettani, G., Giordano, P., Iacoacci, C., Spannella, F., & Sarzani, R. (2020) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00396-9 · Cited by 153
Villa, A., Wolff, Ä., Narayana, N., Dawes, C., Aframian, D., Pedersen, A. M. L., Vissink, A., Aliko, A., Sia, Y. W., Joshi, R. K., et al. (2015) · Oral Diseases · doi:10.1111/odi.12402 · Cited by 145
Tobacco use disorder and cardiovascular health
Benowitz, N. L., & Liakoni, E. (2021) · Addiction · doi:10.1111/add.15703 · Cited by 133
Nicotine receptor partial agonists for smoking cessation
Livingstone‐Banks, J., Fanshawe, T. R., Thomas, K. H., Theodoulou, A., Hajizadeh, A., Hartman, L., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub8 · Cited by 165
Discovery and development of varenicline for smoking cessation
Jordan, C. J., & Xi, Z. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1458090 · Cited by 113
Hancock, D. B., Reginsson, G. W., Gaddis, N. C., Chen, X., Saccone, N. L., Lutz, S. M., Qaiser, B., Sherva, R., Steinberg, S., Zink, F., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.149 · Cited by 85
European Code against Cancer, 4th Edition: Tobacco and cancer
Leon, M. E., Peruga, A., McNeill, A. D., Králíková, E., Guha, N., Minozzi, S., Espina, C., & Schüz, J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.06.001 · Cited by 110
Cytisinicline for Smoking Cessation: A Randomized Clinical Trial
Rigotti, N. A., Benowitz, N. L., Prochaska, J. J., Leischow, S. J., Nides, M. A., Blumenstein, B. A., Clarke, A., Cain, D. F., & Jacobs, C. A. (2023) · JAMA · doi:10.1001/jama.2023.10042 · Cited by 119
Interventions for Tobacco Smoking
Schlam, T. R., & Baker, T. B. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185602 · Cited by 92
Lobeline for smoking cessation
Stead, L. F., & Hughes, J. R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000124.pub2 · Cited by 82
Leaviss, J., Sullivan, W., Ren, S., Everson-Hock, E., Stevenson, M., Stevens, J. W., Strong, M., & Cantrell, A. (2014) · Health Technology Assessment · doi:10.3310/hta18330 · Cited by 79
Cytisine and cytisine derivatives. More than smoking cessation aids
Gotti, C., & Clementi, F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105700 · Cited by 96
Pérez, E. G., Méndez‐Gálvez, C., & Cassels, B. K. (2012) · Natural Product Reports · doi:10.1039/c2np00100d · Cited by 79
Nicotine Vaccines to Assist with Smoking Cessation: Current Status of Research
Raupach, T., Hoogsteder, P., & van Schayck, O. C. P. (2012) · Drugs · doi:10.2165/11599900-000000000-00000 · Cited by 83
Hoogsteder, P., Kotz, D., van Spiegel, P. I., Viechtbauer, W., & van Schayck, O. C. P. (2014) · Addiction · doi:10.1111/add.12573 · Cited by 74
Igari, M., Alexander, J. C., Ji, Y. R., Qi, X., Papke, R. L., & Bruijnzeel, A. W. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.216 · Cited by 78
Nicotine receptor partial agonists for smoking cessation
Livingstone‐Banks, J., Fanshawe, T. R., Thomas, K. H., Theodoulou, A., Hajizadeh, A., Hartman, L., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub9 · Cited by 81
Smoking cessation in patients with respiratory disease: existing treatments and future directions
Rigotti, N. A. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70063-8 · Cited by 70
Avoidable Deaths from Smoking: A Global Perspective
Jha, P. (2011) · Public Health Reviews · doi:10.1007/bf03391651 · Cited by 66
Jackson, S. E., McGowan, J., Ubhi, H. K., Proudfoot, H., Shahab, L., Brown, J., & West, R. (2019) · Addiction · doi:10.1111/add.14549 · Cited by 64
Self-citationStapleton, J. A., & West, R. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr236 · Cited by 62
Self-citationGlobal Hazards of Tobacco and the Benefits of Smoking Cessation and Tobacco Taxes
Jha, P., MacLennan, M., Chaloupka, F. J., Yürekli, A., Ramasundarahettige, C., Palipudi, K. M., Zatonksi, W., Asma, S., & Gupta, P. C. (2015) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0349-9_ch10 · Cited by 73
Śliwiński, P., Górecka, D., Jassem, E., & Pierzchała, W. (2014) · Advances in respiratory medicine · doi:10.5603/piap.2014.0030 · Cited by 81
Cytisine, the world's oldest smoking cessation aid
Prochaska, J. J., Das, S., & Benowitz, N. L. (2013) · BMJ · doi:10.1136/bmj.f5198 · Cited by 60
Non‐pharmacological treatments for COPD
Mulhall, P., & Criner, G. J. (2016) · Respirology · doi:10.1111/resp.12782 · Cited by 66
Improving smoking cessation approaches at the individual level
Aveyard, P. N., & Raw, M. (2012) · Tobacco Control · doi:10.1136/tobaccocontrol-2011-050348 · Cited by 61
Self-citationMechanisms for nicotine in the development and progression of gastrointestinal cancers.
Jensen, K. J., Afroze, S. H., Munshi, K., Guerrier, M., & Glaser, S. S. (2012) · PubMed · doi:10.3978/j.issn.2224-4778.2011.12.01 · Cited by 69
South African tobacco smoking cessation clinical practice guideline
van Zyl-Smit, R. N., Allwood, B., Stickells, D., Symons, G., Abdool-Gaffar, S., Murphy, K., Lalloo, U., Vanker, A., Dheda, K. U. J., & Richards, G. A. (2013) · South African Medical Journal · doi:10.7196/samj.7484 · Cited by 57
Jeong, S. H., Newcombe, D. A. L., Sheridan, J. L., & Tingle, M. D. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1707 · Cited by 61
Tobacco control in the Russian Federation- a policy analysis
Lunze, K., & Migliorini, L. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-64 · Cited by 47
“Although it has been suggested to be effective for smoking cessation and have some potential for smoking cessation therapies in low- and mid-income countries due to its lower costs than other pharmacotherapies [51], the drug has remained largely unnoticed in the English-language literature and in countries outside of…”
BackgroundAndreas, S., Batra, A., Behr, J., Chenot, J., Gillissen, A., Hering, T., Herth, F. J. F., Kreuter, M., Meierjürgen, R., Mühlig, S., et al. (2014) · Pneumologie · doi:10.1055/s-0034-1365052 · Cited by 53
Pastorino, U., Ladisa, V., Trussardo, S., Sabia, F., Rolli, L., Valsecchi, C., Ledda, R. E., Milanese, G., Suatoni, P., Boeri, M., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.07.007 · Cited by 49
The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2012) · The Scientific World Journal · doi:10.1100/2012/104105 · Cited by 44
Shahab, L., Brose, L. S., & West, R. (2013) · CNS Drugs · doi:10.1007/s40263-013-0116-4 · Cited by 53
Self-citationBarik, A., Kumar, R., Gorain, A., Majumdar, S., & Chowdhury, A. (2015) · Perspectives in Public Health · doi:10.1177/1757913915609947 · Cited by 48
Cytisine for smoking cessation: A systematic review and meta-analysis
Ofori, S., Lu, C., Olasupo, O. O., Dennis, B. B., Fairbairn, N. S., Devereaux, P. J., & Mbuagbaw, L. C. E. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110936 · Cited by 42
Emerging drugs for the treatment of tobacco dependence: 2014 update
Elrashidi, M. Y., & Ebbert, J. O. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.899580 · Cited by 46
Dogar, O. F., Keding, A., Gabe, R., Marshall, A., Huque, R., Barua, D., Fatima, R., Khan, A., Zahid, R., Mansoor, S., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30312-0 · Cited by 48
Hoogsteder, P., Kotz, D., van Spiegel, P. I., Viechtbauer, W., Brauer, R., Kessler, P., Kalnik, M. W., Fahim, R. E. F., & van Schayck, O. C. P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-1052 · Cited by 39
Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine
Campello, H. R., del Villar, S. G., Honraedt, A., Minguez, T., Oliveira, A. S. F., Ranaghan, K. E., Shoemark, D. K., Bermúdez, I., Gotti, C., Sessions, R. B., et al. (2018) · Chem · doi:10.1016/j.chempr.2018.05.007 · Cited by 42
Rigotti, N. A., Benowitz, N. L., Prochaska, J. J., Cain, D. F., Ball, J., Clarke, A., Blumenstein, B. A., & Jacobs, C. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.1313 · Cited by 47
Cytisine for smoking cessation
Karnieg, T., & Wang, X. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.171371 · Cited by 37
Rollema, H., & Hurst, R. S. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4921-9 · Cited by 51
Nides, M. A., Rigotti, N. A., Benowitz, N. L., Clarke, A., & Jacobs, C. A. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab073 · Cited by 50
Masihuddin, M., Jafri, M., Siddiqui, A., & Chaudhary, S. S. (2018) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v8i5-s.2069 · Cited by 36
Probing Binding Interactions of Cytisine Derivatives to the α4β2 Nicotinic Acetylcholine Receptor.
Blom, A. M., Campello, H., Lester, H., Gallagher, T., & Dougherty, D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06580 · Cited by 22
Getting cytisine licensed for use world-wide: a call to action
Walker, N. K., Bullen, C., Barnes, J., McRobbie, H. J., Tutka, P., Raw, M., Etter, J., Siddiqi, K., Courtney, R. J., Castaldelli-Maia, J. M., et al. (2016) · Addiction · doi:10.1111/add.13464 · Cited by 32
Ward, K. D. (2016) · The Journal of Smoking Cessation · doi:10.1017/jsc.2016.6 · Cited by 30
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation
Mohamed, T. S., Jayakar, S. S., & Hamouda, A. K. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00071 · Cited by 29
Systematic review and meta‐analyses of cytisine to support tobacco cessation
Puljević, C., Stjepanović, D., Meciar, I., Kang, H., Chan, G., Morphett, K., Bendotti, H., Kunwar, G., & GARTNER, C. E. (2024) · Addiction · doi:10.1111/add.16592 · Cited by 33
Dogar, O. F., Barua, D., Boeckmann, M., Elsey, H., Fatima, R., Gabe, R., Huque, R., Keding, A., Khan, A., Kotz, D., et al. (2018) · Addiction · doi:10.1111/add.14242 · Cited by 25
Tindle, H. A., Freiberg, M. S., Cheng, D. M., Gnatienko, N., Blokhina, E. A., Yaroslavtseva, T. V., Bendiks, S., Patts, G. J., Hahn, J. A., So‐Armah, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.25129 · Cited by 28
Santi, O. D., Orellana, M., Niro, C. A. D., & Greco, V. (2023) · Addiction · doi:10.1111/add.16399 · Cited by 27
Human pharmacology for addiction medicine
Quednow, B. B., & Herdener, M. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.017 · Cited by 27
Substituting medicinal plants through drug synthesis
Sengupta, G., Gaurav, A., & Tiwari, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102071-5.00003-9 · Cited by 25
McRobbie, H. J., Raw, M., & Chan, S. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts244 · Cited by 22
Jin, Z., Khan, P. M., Shin, Y., Wang, J., Li, L., Cameron, M. D., Lindstrom, J. M., Kenny, P. J., & Kamenecka, T. M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.049 · Cited by 22
Pandita, D., & Pandita, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-58975-2_2 · Cited by 32
An update on the pharmacotherapeutic interventions for smoking cessation
Barboza, J., Patel, R., Patel, P. P., & Hudmon, K. S. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1197203 · Cited by 19
Thomas, D., Farrell, M., McRobbie, H. J., Tutka, P., Petrie, D., West, R., Siahpush, M., GARTNER, C. E., Walker, N. K., Mendelsohn, C. P., et al. (2018) · Addiction · doi:10.1111/add.14541 · Cited by 31
Self-citationPriorities for tobacco control research in I ndia
Sarkar, B. K., & Reddy, K. S. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03942.x · Cited by 20
Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial
Rigotti, N. A., Benowitz, N. L., Prochaska, J. J., Rubinstein, M., Clarke, A., Blumenstein, B. A., Cain, D. F., & Jacobs, C. A. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.0628 · Cited by 30
Antoniu, S. A., Buculei, I., Mihaltan, F. D., Crișan-Dabija, R. A., & Trofor, A. C. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1858796 · Cited by 19
Orešković, T., Percac‐Lima, S., Ashburner, J. M., Tiljak, H., Rifel, J., Klemenc–Ketiš, Z., & Orešković, S. (2023) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntad065 · Cited by 23
Walker, N., Howe, C., Bullen, C., McRobbie, H., Glover, M., Parag, V., Williman, J., Veale, R., Nosa, V., & Barnes, J. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-880 · Cited by 18
Cytisine and the failure to market and regulate for human health
Aveyard, P. N., & West, R. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203246 · Cited by 18
Self-citationPharmacotherapies and harm-reduction options for the treatment of tobacco dependence
Houezec, J. L., & Aubin, H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.818978 · Cited by 20
How to manage cigarette smoking in kidney transplant candidates and recipients?
Devresse, A., Gohy, S. T., Robert, A., & Kanaan, N. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab072 · Cited by 16
Metadata
- Authors
- West, R., Zatonski, W., Cedzynska, M., Lewandowska, D., Pazik, J., Aveyard, P., & Stapleton, J.
- Affiliations
- Cancer Research UK (GB)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-29
- Volume
- 365
- Issue
- 13
- Pages
- 1193-1200
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2023431702
- Cited by
- 234
- References
- 25
- Citations by year
- 2026: 14 · 2025: 11 · 2024: 13 · 2023: 11 · 2022: 21 · 2021: 13 · 2020: 9 · 2019: 10 · 2018: 16 · 2017: 10 · 2016: 11 · 2015: 14 · 2014: 16 · 2013: 28 · 2012: 28
- FWCI
- 17.19
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research Portal (King's College London) (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Cancer Research UK
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- cytisine, smoking cessation, nicotine dependence, nicotinic acetylcholine receptors, smoking abstinence, pharmacotherapy, gastrointestinal adverse effects, low-cost treatment
- MeSH terms
- Adult, Cystine, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Placebos, Smoking Cessation, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.